
Charlotte Teunissen
Professor of Neurochemistry and Head of the Neurochemistry Laboratory at Amsterdam UMC, a leading researcher on fluid biomarkers for neurodegenerative diseases.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
Sep 9, 2026
The future of Alzheimer’s disease: blood biomarkers, brain imaging, and screening the cognitively unimpaired
10:13
10:20
10:36
10:49
12:31

Laura HartHOST
So is real-world testing already moving faster than the guidance can keep up with and what would help close that gap?

Charlotte TeunissenGUEST
Well, I would say that there are also positive things ongoing, that testing is already being used in the right context.

Charlotte TeunissenGUEST
Using high quality tests and also that there is interpretation of the test results done by healthcare professionals that are experts in cognitive problems.

Charlotte TeunissenGUEST
But the use of the direct-to-consumer test, that goes a little bit outside the control.

Laura HartHOST
And can you expand a little bit more on what the most urgent unmet need is for fluid biomarker development?